10-Q: Vaxart Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxart's Q3 2024 report highlights progress in clinical trials and financial activities, including a significant government contract and capital raises.

Summary

• Vaxart's Q3 2024 financial results show a net loss of $14.08 million, or $0.06 per share, compared to a net loss of $17.4 million, or $0.11 per share, in Q3 2023.
• The company's revenue increased to $4.93 million in Q3 2024, up from $2.1 million in Q3 2023, primarily due to government contract revenue.
• For the nine months ended September 30, 2024, Vaxart reported a net loss of $54.96 million, or $0.28 per share, compared to a net loss of $65.09 million, or $0.45 per share, for the same period in 2023.
• The company's revenue for the first nine months of 2024 was $13.51 million, compared to $4.13 million for the same period in 2023.
• Vaxart secured a contract with HHS BARDA for up to $456.1 million to conduct a Phase 2b study and manufacture a COVID-19 vaccine candidate targeting the KP.2 strain.
• As of September 30, 2024, Vaxart had cash, cash equivalents, and short-term investments totaling $58.7 million.
• The company issued 50 million shares of common stock at $0.80 per share in June 2024, raising net proceeds of $37.5 million.
• Vaxart also sold 15.38 million shares of common stock to RA Capital Healthcare Fund, L.P. at $0.65 per share in January 2024, raising net proceeds of $9.9 million.
• The company terminated its September 2021 ATM facility on October 18, 2024, after raising $28.6 million through the sale of 17.5 million shares.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as the large government contract and successful capital raises, the company continues to operate at a loss and faces significant risks. The sentiment is cautiously optimistic, reflecting the potential of the technology but also the challenges ahead.

Positives

• Vaxart's revenue increased significantly due to government contracts, indicating progress in securing funding for its programs.
• The company secured a substantial contract with HHS BARDA, providing significant funding for its COVID-19 vaccine development.
• Vaxart successfully raised capital through multiple offerings, strengthening its financial position.
• The initiation of the Phase 2b clinical trial for the oral COVID-19 vaccine is a key milestone.
• The company has a strong cash position of $58.7 million, providing a runway into 2026.

Negatives

• Vaxart continues to experience net losses, although the loss per share has decreased compared to the previous year.
• The company's non-cash royalty revenue related to the sale of future royalties decreased significantly.
• Research and development expenses remain high, reflecting the ongoing costs of clinical trials and development activities.
• The company is dependent on raising additional capital to continue operations.

Risks

• Vaxart is dependent on government funding, and any reduction or delay in funding could negatively impact its operations.
• The company's stock price has been below the Nasdaq minimum bid price, which could lead to delisting.
• The company is subject to risks associated with clinical trials, including the possibility of unfavorable results or delays.
• Vaxart faces competition from other companies developing vaccines and therapeutics.
• The company's ability to commercialize its products is subject to regulatory approvals and market acceptance.

Future Outlook

Vaxart expects to incur significant research and development expenses as it advances its vaccine candidates through clinical trials and seeks regulatory approvals. The company will be dependent on raising additional capital through placement of its common stock, notes or other securities, borrowings, or entering into a partnership with a strategic party in order to implement its business plan.

Management Comments

• Management believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement.
• Management believes that if the 2024 ATI-RRPV Contract were to be terminated prior to completion of the Phase 2b comparative study, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs.

Industry Context

The announcement comes amid ongoing efforts to develop effective vaccines and treatments for COVID-19 and other infectious diseases. Vaxart's oral vaccine platform offers a unique approach compared to traditional injectable vaccines, potentially providing advantages in terms of ease of administration and distribution. The company's focus on mucosal immunity also aligns with growing interest in developing vaccines that can provide broader protection against respiratory pathogens.

Comparison to Industry Standards

• Vaxart's Phase 2b trial for its oral COVID-19 vaccine is a significant step, comparable to other companies advancing their vaccine candidates through clinical development.
• The company's focus on mucosal immunity is a differentiating factor, as most COVID-19 vaccines are administered via injection.
• The $456.1 million contract with HHS BARDA is a substantial funding commitment, reflecting the potential of Vaxart's technology.
• The company's financial results are typical for a clinical-stage biotechnology company, with significant research and development expenses and reliance on external funding.
• Vaxart's cash position of $58.7 million is relatively strong compared to some other companies in the sector, but it will need to continue to raise capital to fund its operations.

Legal Proceedings

• The company is involved in ongoing legal proceedings, including a securities class action lawsuit and a lawsuit related to short-swing profits.
• The company reached a partial settlement in the securities class action lawsuit, agreeing to pay $2 million, with the remainder to be paid by its insurers.
• A motion for summary judgment was granted in the short-swing profits lawsuit, dismissing all claims, but the plaintiff has appealed the decision.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and stock price volatility.
• Employees are affected by the company's financial stability and ability to continue operations.
• Customers (potential future purchasers of vaccines) are impacted by the company's ability to successfully develop and commercialize its products.
• Suppliers and creditors are impacted by the company's ability to meet its financial obligations.

Next Steps

• Vaxart will continue to enroll participants in its Phase 2b clinical trial for its oral COVID-19 vaccine.
• The company will manufacture a COVID-19 vaccine candidate targeting the KP.2 strain.
• Vaxart will continue to pursue regulatory approvals for its vaccine candidates.
• The company will continue to seek additional funding to support its operations.

Key Dates

Keywords

COVID-19 vaccine, oral vaccine, clinical trial, HHS BARDA, Phase 2b, government contract, capital raise, biotechnology, VXA-CoV2, norovirus vaccine